» Articles » PMID: 35326586

Imaging of Oligometastatic Disease

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Mar 25
PMID 35326586
Authors
Affiliations
Soon will be listed here.
Abstract

Oligometastatic disease (OMD) is an emerging state of disease with limited metastatic tumor burden. It should be distinguished from polymetastatic disease due the potential curative therapeutic options of OMD. Imaging plays a pivotal role in the diagnosis and follow-up of patients with OMD. The imaging tools needed in the case of OMD will differ according to different parameters, which include primary tumor type, timing between measurement and treatment, potential metastatic location and the patient's individual risk for metastasis. In this article, OMD is defined and the use of different imaging modalities in several oncologic situations are described in order to better understand OMD and its specific implication for radiologists.

Citing Articles

A Bibliometric Analysis of the Oligometastatic State over the Last Two Decades: A Shifting Paradigm for Oncology? An AIRO Oligometastatic Study Group.

Marvaso G, Mastroleo F, Corrao G, Zaffaroni M, Vincini M, Borghetti P Cancers (Basel). 2023; 15(15).

PMID: 37568718 PMC: 10417037. DOI: 10.3390/cancers15153902.

References
1.
Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz J, Denkert C . The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2014; 6(1):570-83. PMC: 4381616. DOI: 10.18632/oncotarget.2677. View

2.
Iagaru A, Quon A, McDougall I, Gambhir S . F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas. Clin Nucl Med. 2006; 31(12):754-60. DOI: 10.1097/01.rlu.0000246846.01492.31. View

3.
Treglia G, Mestre R, Ferrari M, Bosetti D, Pascale M, Oikonomou E . Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis. Am J Nucl Med Mol Imaging. 2019; 9(2):127-139. PMC: 6526363. View

4.
Albala D . Imaging and treatment recommendations in patients with castrate-resistant prostate cancer. Rev Urol. 2018; 19(3):200-202. PMC: 5737351. DOI: 10.3909/riu193PracticeProfile. View

5.
Eberhardt W, Mitchell A, Crowley J, Kondo H, Kim Y, Turrisi 3rd A . The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2015; 10(11):1515-22. DOI: 10.1097/JTO.0000000000000673. View